July 31 Quick Takes: FDA approves MorphoSys’ tafasitamab; Truvian, AbbVie, Boehringer, Lilly, Alector, Henlius-Accord, Ascletis, Roche, Merck

MorphoSys follows Kress’ first big deal with U.S. approval

FDA granted accelerated approval to Monjuvi tafasitamab-cxix from MorphoSys AG (Xetra:MOR; NASDAQ:MOR) and Incyte Corp. (NASDAQ:INCY) in combination with lenalidomide to treat patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) not eligible for autologous stem cell transplant. The therapy was the subject of the first major deal under MorphoSys’ new CEO

Read the full 629 word article

How to gain access

Continue reading with a
two-week free trial.